Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organization (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities. Following completion of Metrion’s £3.
7M equity financing in December 20231, the Company has made several high-profile appointments2. Chris’ appointment as CCO further strengthens the senior management team, enhancing its scientific and commercial capabilities, and continue to drive expansion in key global markets. Chris is a well-respected industry leader with over 25 years of experience in the biopharmaceutical sector, specializing in the preclinical CRO space and developing high-performance sales and marketing strategies.
He has held several executive-level positions, at Sophion Bioscience, ChanTest (now part of Charles River Laboratories), Icagen and AnaBios, where he provided strategic support to guide business development and overall strategy. Over the last few months Chris has also been advising Metrion on business development in the USA. Chris holds a PhD in Neuroscience from the University of California, Los Angeles (UCLA) and an MBA from Rutgers University.
He completed his post-doctoral research at Stanford University and the Max Planck Institute for Biophysical Chemistry, fo.